Editorial: Clinical prescribing (and off-label use) in a second-best world

Medical Care

Volumn 48, Issue 4, 2010, Pages 285-287

  Alexander, G Caleb ^a,b,c,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; GABAPENTIN; NEUROLEPTIC AGENT; PREGABALIN;

BIPOLAR DISORDER; DRUG APPROVAL; DRUG COST; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LEGAL LIABILITY; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; LEGAL ASPECT; NOTE; POLYPHARMACY; UNITED STATES;

HUMANS; OFF-LABEL USE; POLYPHARMACY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77950248165     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181d60408     Document Type: Editorial

References (31)

1. Dai C, Stafford RS, Alexander GC. National trends in Cyclooxygenase-2 inhibitor use since market release: non-selective diffusion of a selectively cost-effective innovation. Arch Intern Med. 2005;165:171-177.
2. Hully SB, Grady D, Brownder WS. Statins: underused by those who would benefit. BMJ. 2000;321:971-972.
3. Kroutil LA, Van Brunt DL, Herman-Stahl MA, et al. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006;84:135-143.
4. Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52:1349-1354.
5. Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870-2874.
6. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
7. Osterberg L, Glaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
8. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medicines and dietary supplements among older adults in the United States: findings from a population-based study. JAMA. 2008;300:2867-2878.
9. Kennedy J, Wang CC, Wu CH. Patient disclosure about herb and supplement use among adults in the US. Evid Based Complement Alternat Med. 2008;5:451-456.
10. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's Disease. N Engl J Med. 2006;355:1525-1538.
11. Huntzinger A. FDA warns against off-label use of antipsychotic drugs. Am Fam Physician. 2005;71:2205.
12. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021-1026.
13. Goldstein J. Lilly in settlement talks over Zyprexa marketing. The Wall Street Journal. January 30, 2008.
14. Purdue in $634 million settlement over OxyContin: Purdue Pharma to pay $634 million to settle 4-year investigation over OxyContin painkiller marketing. CNN Money. July 20, 2007. Available at: http://money. cnn.com/2007/07/20/news/companies/purdue/index.htm. Accessed January 12, 2010.
15. United States Government Accountability Office: Report to the ranking member, Committee on Finance, U.S. Senate. Prescription drugs: FDA's oversight of the promotion of drugs for off-label uses. July 2008. GAO-08-835. Available at: http://www.gao.gov/new.items/d08835. pdf. Accessed January 12, 2010.
16. Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. Med Care. 2010;48:372-379.
17. Larkin M. Warner-Lambert found guilty of promoting Neurontin off label. Lancet Neurol. 2004;3:387.
18. Steinman MA, Bero LA, Chren MM, et al. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284-293.
19. Barber N. What constitutes good prescribing? BMJ. 1995;310:923-925.
20. Special Report: the publication of new evidence and effect on physician prescribing behaviors. Technol Eval Cent Assess Program Exec Summ. 2004;19:1-3.
21. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
22. Suh DC, Manning WG, Schondelmeyer S, et al. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Serv Res. 2000;35:529-547.
23. Walton SM, Schumock GT, Lee KV, et al. Prioritizing medications for policy and research initiatives examining off-label prescribing. Pharma-cotherapy. 2008;28:1443-1452.
24. Chen DT, Wynia MK, Moloney RM, et al. Physician knowledge of the FDA-approved indications of commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf. 2009;18:1-7.
25. Food and Drug Administration. Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices (Draft Guidelines). Rockville, MD: Food and Drug Administration; 2008.
26. FDA's Safe Use Initiative: Collaborating to reduce preventable harm from medications. U.S. Department of Health and Human Services, Food and Drug Administration. November 4 2009. Available at: http://www.fda.gov/drugs/ drugsafety/ucm187806.htm. Accessed January 21 2010.
27. Topol EJ. Failing the public health-rofecoxib, merck and the FDA. N Engl J Med. 2004;351:1707-1709.
28. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-related regulatory actions for biologicals approved in United States and European Union. JAMA. 2008;300:1887-1896.
29. Gillick MR. Controlling off-label medication use. Ann Intern Med. 2009;150:344-347.
30. Naylor CD. The complex world of prescribing behavior. JAMA. 2004; 291:104-106.
31. Alexander GC, Stafford RS. Does comparative effectiveness have a comparative edge? JAMA. 2009;301:2488-2490.